TECH & SPACE
🇬🇧
Povratak
🇬🇧 EN
Medicinadb#1027

Probiotici postali lovci na tumore: što studija stvarno pokazuje

(2w ago)
Global
sciencedaily.com
Probiotici postali lovci na tumore: što studija stvarno pokazuje

Probiotici postali lovci na tumore: što studija stvarno pokazuje📷 © Tech&Space

  • ★Modificirani *E. coli* Nissle 1917 proizvode lijek unutar tumora
  • ★Testirano samo na miševima – ljudska ispitivanja još daleko
  • ★Potencijal za smanjene nuspojave, ali ostaju ključna pitanja sigurnosti

Znanstvenici su uspjeli pretvoriti probiotičke bakterije u mini-tvornice lijekova koje ciljano napadaju tumore – ali za sada samo u laboratoriju i na glodavcima. Modificirana soj Escherichia coli Nissle 1917 (EcN), probiotik s dugom poviješću sigurne upotrebe, genetski je reprogramirana da proizvodi Romidepsin (FK228), odobreni antikancerogeni lijek, direktno unutar tumorskog tkiva.

Rezultati objavljeni u časopisu PLOS Biology pokazuju da su bakterije uspješno kolonizirale tumore kod miševa i lokalno oslobodile lijek, što je rezultiralo smanjenjem rasta tumora. Ovo nije prvi pokušaj korištenja bakterija za borbu protiv raka, ali je jedan od rijetkih koji kombinira probiotičku sigurnost s preciznom isporukom lijeka.

Ključna prednost pristupa leži u potencijalu za smanjenje sistemskih nuspojava – umjesto da lijek putuje krvotokom i utječe na zdravo tkivo, proizvodi se točno tamo gdje je potreban. Međutim, čitav koncept ostaje u ranoj istraživačkoj fazi: studija je provedena na ograničenom broju životinjskih modela, a mehanizmi dugoročne sigurnosti – posebno pitanje kako ukloniti bakterije nakon tretmana – još nisu riješeni.

Važno je istaknuti da se radi o prekliničkom istraživanju, a ne o terapiji spremnoj za ljude. Romidepsin je već odobren za upotrebu kod određenih limfoma, ali njegova kombinacija s živim bakterijama zahtijeva potpuno nova ispitivanja sigurnosti. "Escherichia coli Nissle 1917-ina kolonizacija tumora sinergijski djeluje s antikancerogenom aktivnošću Romidepsina", navode autori, ali upozoravaju da je za kliničku primjenu potrebno "razviti strategije za kontrolu bakterijske populacije nakon tretmana".

Razina dokaza: istraživački stadij s jasnim granicama primjene

Razina dokaza: istraživački stadij s jasnim granicama primjene📷 © Tech&Space

Razina dokaza: istraživački stadij s jasnim granicama primjene

Za razliku od tradicionalne kemoterapije koja napada sve brzo dijeljenje stanice, ovaj pristup cilja isključivo na mikrookoliš tumora. Bakterije EcN prirodno teže hipoksijskim (kiseonikom siromašnim) područjima, koja su karakteristična za unutrašnjost tumora, što ih čini idealnim kandidatima za "transportne" sisteme.

Međutim, čak i ako se pokaže sigurnim kod ljudi, ostaje pitanje koliko će ovaj metod biti učinkovit protiv različitih vrsta karcinoma – studija se usredotočila na specifične modele mišjih tumora, a ljudska biologija je daleko kompleksnija. Još jedna nepoznanica je imunološki odgovor: tijelo može prepoznati i napasti modificirane bakterije prije nego što one dostignu tumor, ili pak prekomjerno reagirati i izazvati upalu.

Autori ističu potrebu za daljnjim istraživanjima imunološke tolerancije i mogućih interakcija s postojećim terapijama. Za pacijente danas ovo ne mijenja ništa – ali otvara vrata novim studijama koje bi mogle kombinirati mikrobiološke i farmakološke pristupe.

Regulatorni put do odobrenja takvog tretmana bio bi dug: najprije bi trebala uslijediti ispitivanja na većem uzorku životinja, zatim faze 1 i 2 kliničkih studija na ljudima (s fokusom na sigurnost), te tek onda procjena učinkovitosti. Prema podacima Svjetske zdravstvene organizacije, rak je drugi najčešći uzrok smrti globalno, što čini potrebu za inovativnim terapijama hitnom – ali i oprezom u procjeni novih pristupa.

ProbioticsCancer TreatmentOncology Research

//Comments

Uredi u foto-review →
AIAmazon’s $50B OpenAI bet: Trainium’s real test begins nowRoboticsHumanoid Tennis: Demo That Still Doesn't Play a Real MatchAIGoogle’s Gemini games flop: AI hype hits gamer realityRoboticsAtlas Redefines Humanoid DesignAINvidia’s AI tax: half your salary or half your careerRoboticsOne antenna, two worlds: robot sniffs out realityAITriangle Health’s $4M AI won’t replace your doctor—yetRoboticsDrone swarms take flight—but not off the demo lot yetAIHumble AI is just healthcare’s latest buzzword for ‘don’t trust us yet’SpaceMapping the Local Bubble’s magnetic field reshapes cosmic scienceAIOpenAI’s teen safety tools: open source or open question?SpaceStarship’s Tenth Test: The Reusability Threshold CrossedAITinder’s AI gambit: swiping left on endless swipingSpaceMeta Shuts VR PiratesAINVIDIA’s Alpamayo AI: Self-Driving’s Hardest Problem or Just Another Demo?SpaceJWST peels back dust to reveal star birth in W51AIWaymo’s police problem exposes AV’s real-world blind spotsSpaceAI’s Copyright Chaos Threatens Space Exploration DataAILittlebird’s $11M bet: AI that reads your screen—without the screenshotsSpaceExoplanet spins confirm a planetary mass ruleAIUK firms drown in AI hype, emerge with empty spreadsheetsGamingCrimson Desert’s AI art fail: a mockup that slipped throughAIOpenAI’s erotic chatbot pause is a rare win for ethics over hypeGamingPearl Abyss hid AI assets in Crimson Desert—now players want answersAIApple’s Gemini Distillation: On-Device AI Without the Cloud HypeGamingCapcom Rejects AI AssetsAICapcom’s AI partner talk is just corporate speak for ‘we’ll use it carefully’GamingWine 11: Linux gaming just got its first real power-up in yearsAIOpenSeeker’s open gambit: Can 11K data points break AI’s data monopoly?TechnologyTaiwan’s chip giants bet on helium and nukes to dodge supply shocksAIGimlet Labs Solves AI BottleneckTechnologySignal’s phishing crisis exposes the limits of encrypted trustAIHelion Powers OpenAIMedicineProstate cancer atlas maps earliest cellular changesAINVIDIA’s OpenShell: Security for AI Agents or Just Another Hype Shell?MedicineTelmisartan Boosts Cancer TreatmentAIDRAFT Boosts AI SafetyMedicineXaira Unveils X-CellAIProject Glasswing: AI finds flaws everywhere—except in its own hypeMedicineAI Fails to Speed Lung Cancer DiagnosisAIPAM: Complex Math for a 10% Performance HitAIOpenAI’s erotic chatbot pause exposes AI’s adult content dilemmaAIAI Ranks Recovery Factors—but Who’s Really Listening?AIDeepMind’s AI safety play: real guardrails or just another demo?AILSD for MLLMs: Reinforcement Learning Cuts the Demo FatAIMicrosoft’s 700B AI bet: Hype or a real retail crystal ball?AIAdobe & NVIDIA’s real-time trick shouldn’t work—but it doesAIEmbeddings hit their limits—and no one’s checking the fine printAIAmazon’s $50B OpenAI bet: Trainium’s real test begins nowRoboticsHumanoid Tennis: Demo That Still Doesn't Play a Real MatchAIGoogle’s Gemini games flop: AI hype hits gamer realityRoboticsAtlas Redefines Humanoid DesignAINvidia’s AI tax: half your salary or half your careerRoboticsOne antenna, two worlds: robot sniffs out realityAITriangle Health’s $4M AI won’t replace your doctor—yetRoboticsDrone swarms take flight—but not off the demo lot yetAIHumble AI is just healthcare’s latest buzzword for ‘don’t trust us yet’SpaceMapping the Local Bubble’s magnetic field reshapes cosmic scienceAIOpenAI’s teen safety tools: open source or open question?SpaceStarship’s Tenth Test: The Reusability Threshold CrossedAITinder’s AI gambit: swiping left on endless swipingSpaceMeta Shuts VR PiratesAINVIDIA’s Alpamayo AI: Self-Driving’s Hardest Problem or Just Another Demo?SpaceJWST peels back dust to reveal star birth in W51AIWaymo’s police problem exposes AV’s real-world blind spotsSpaceAI’s Copyright Chaos Threatens Space Exploration DataAILittlebird’s $11M bet: AI that reads your screen—without the screenshotsSpaceExoplanet spins confirm a planetary mass ruleAIUK firms drown in AI hype, emerge with empty spreadsheetsGamingCrimson Desert’s AI art fail: a mockup that slipped throughAIOpenAI’s erotic chatbot pause is a rare win for ethics over hypeGamingPearl Abyss hid AI assets in Crimson Desert—now players want answersAIApple’s Gemini Distillation: On-Device AI Without the Cloud HypeGamingCapcom Rejects AI AssetsAICapcom’s AI partner talk is just corporate speak for ‘we’ll use it carefully’GamingWine 11: Linux gaming just got its first real power-up in yearsAIOpenSeeker’s open gambit: Can 11K data points break AI’s data monopoly?TechnologyTaiwan’s chip giants bet on helium and nukes to dodge supply shocksAIGimlet Labs Solves AI BottleneckTechnologySignal’s phishing crisis exposes the limits of encrypted trustAIHelion Powers OpenAIMedicineProstate cancer atlas maps earliest cellular changesAINVIDIA’s OpenShell: Security for AI Agents or Just Another Hype Shell?MedicineTelmisartan Boosts Cancer TreatmentAIDRAFT Boosts AI SafetyMedicineXaira Unveils X-CellAIProject Glasswing: AI finds flaws everywhere—except in its own hypeMedicineAI Fails to Speed Lung Cancer DiagnosisAIPAM: Complex Math for a 10% Performance HitAIOpenAI’s erotic chatbot pause exposes AI’s adult content dilemmaAIAI Ranks Recovery Factors—but Who’s Really Listening?AIDeepMind’s AI safety play: real guardrails or just another demo?AILSD for MLLMs: Reinforcement Learning Cuts the Demo FatAIMicrosoft’s 700B AI bet: Hype or a real retail crystal ball?AIAdobe & NVIDIA’s real-time trick shouldn’t work—but it doesAIEmbeddings hit their limits—and no one’s checking the fine print
⊞ Foto Review